News & Updates
Filter by Specialty:
Prednisone better than anakinra-zinc combo for severe alcohol-associated hepatitis
Use of prednisone in patients with severe alcohol-associated hepatitis (SAH) results in significantly better overall and transplant-free survival at 90 days and a lower incidence of acute kidney injury (AKI) when compared with the use of anakinra plus zinc, results of a study have shown.
Prednisone better than anakinra-zinc combo for severe alcohol-associated hepatitis
18 May 2024
HCV cure possible in people who inject drugs despite poor treatment adherence
People who inject drugs (PWID) with low adherence to sofosbuvir/velpatasvir can still be cured of hepatitis C virus (HCV) infection, suggests a study.
HCV cure possible in people who inject drugs despite poor treatment adherence
17 May 2024
Long-term data strengthen TAK-003 potential against dengue
The live-attenuated tetravalent dengue vaccine TAK-003 showed cumulative long-term efficacy in preventing symptomatic dengue caused by all four dengue virus (DENV) serotypes among previously exposed children and adolescents, and by DENV-1 and DENV-2 in dengue-naïve participants in eight* dengue-endemic countries, a study has shown.
Long-term data strengthen TAK-003 potential against dengue
16 May 2024
Biologic DMARDs offer clinical benefits in adult-onset Still disease
Use of biologic disease-modifying antirheumatic drugs (bDMARDs), particularly tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK), appears safe and effective in the treatment of adult-onset Still disease (AOSD), results of a systematic review and meta-analysis have shown.
